Lyell Immunopharma (LYEL) Net Income towards Common Stockholders (2020 - 2026)

Lyell Immunopharma has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$103.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 19.91% year-over-year to -$103.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$465.5 million (up 50.67% YoY) and the FY2025 annual result came in at -$286.5 million, up 60.08% from the prior year.
• Net Income towards Common Stockholders advanced to -$103.2 million in Q1 2026 per LYEL's latest filing, from -$144.7 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$13.6 million in Q4 2022 and troughed at -$561.1 million in Q4 2024.
• A 5-year average of -$149.6 million and a median of -$124.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders jumped 92.31% in 2022, then sank 2163.17% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$13.6 million in 2022, then tumbled by 2163.17% to -$306.8 million in 2023, then plunged by 82.85% to -$561.1 million in 2024, then surged by 74.21% to -$144.7 million in 2025, then climbed by 28.67% to -$103.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$103.2 million, -$144.7 million, and -$102.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.